WB, IP
H M R Mk
Endogenous
45
Rabbit IgG
#Q9NXR7
9577
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gln150 of human BRE protein.
Background
The breast cancer susceptibility gene, BRCA1, codes for an E3 ubiquitin ligase that functions in the maintenance of genome stability through regulation of the DNA damage response and DNA repair. BRCA1 protein forms at least three distinct complexes (BRCA1 A, B, and C) with other DNA repair proteins, and these interactions are vital for regulation of BRCA1 function. The BRCA1 A complex includes Rap80, BRCC36, Abraxas, MERIT40/NBA1, and BRE/BRCC45 and functions in G2/M phase checkpoint control (reviewed in 1,2). MERIT40 and BRE maintain the stability of both the BRCA1 A complex and the cytoplasmic BRISC complex, which contains BRCC36 and ABRO1 but not BRCA1 (3).
Researchers have shown that the expression level of BRE is related to patient survival in breast cancer (4), and it may predict a favorable outcome in acute myeloid leukemia (AML) (5,6). Studies have also shown that BRE is overexpressed in human hepatocellular carcinoma (7) and that overexpression of BRE can cause resistance to apoptotic signaling and promote tumor growth (7,8).
- Ohta, T. et al. (2011) FEBS Lett 585, 2836-44.
- Huen, M.S. et al. (2010) Nat Rev Mol Cell Biol 11, 138-48.
- Hu, X. et al. (2011) J Biol Chem 286, 11734-45.
- Noordermeer, S.M. et al. (2012) Breast Cancer Res Treat 135, 125-33.
- Noordermeer, S.M. et al. (2011) Blood 118, 5613-21.
- Balgobind, B.V. et al. (2010) Leukemia 24, 2048-55.
- Chan, B.C. et al. (2008) Oncogene 27, 1208-17.
- Chui, Y.L. et al. (2010) Biochem Biophys Res Commun 391, 1522-5.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
